A Cohort Study to Evaluate the Real-World Utilization and Effectiveness of Bebtelovimab Compared to Paxlovid among Patients with Mild-to-Moderate COVID-19 Who Are at High Risk for Progressing to Severe Illness (J2X-MC-B003)

09/02/2023
17/06/2024
EU PAS number:
EUPAS50700
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

LY3853113 J2X-MC-B003 RWE Protocol_Redacted

English (1.45 MB - PDF) View document
Updated protocol

LY3853113 J2X-MC-B003(a) RWE Protocol_Redacted

First published: 22/02/2024
English (1.31 MB - PDF) View document
Study results
Study report
Study report

LY3853113_J2X-MC-B003 Full Clinical Study Report_Redacted.pdf

English (2.71 MB - PDF) View document
Other information